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New BMJ policy on economic evaluations
Response of NHS Economic Evaluation
Database Research Team
Editor—We, the NHS Economic Evaluation
Database Research Team, agree with Smith
that economic evaluations should contain
comprehensive reporting of both clinical
effectiveness and economic analysis and that
the BMJ is right to implement this new
policy.1 How the clinical trial results (which
inform the economic evaluation) are
obtained is often paramount to the under›
standing and quality of the economic analy›
sis conducted.2
Research reports are included and
abstracted in full on the NHS Economic
Evaluation Database (www.york.ac.uk/inst/
crd)—if they explicitly report costs and clini›
cal outcomes for an intervention and at least
one comparator.3 However, to critique the
method adopted in the effectiveness study
underpinning the economic evaluation
appropriately, our template requires infor›
mation that is often omitted in the report of
the economic evaluation. When the parent
clinical study has been previously published
elsewhere, we obtain the study and use that
alongside the economic research when writ›
ing the abstract. The abstract on the
database then provides information on sam›
ple selection, study design, method of analy›
sis, and so on, with the fact that the relevant
information is cited from the parent study.
Adhering to published guidelines, such
as those provided by the BMJ,4 should
produce publications of the highest quality,
but authors are still likely to feel the need to
be selective in their reporting, given word
limits. If authors are required to report more
effectiveness data other crucial aspects of the
economic evaluation might receive less
attention. The focus for BMJ editors should
be to ensure that reporting of both
important components of economic evalua›
tions receives appropriate attention from
the authors.
If the policy results in full reporting of
both clinical and economic results in one
place—for example, two papers in one issue
of the journal—this will constitute an
improvement. If, however, the new policy
results in the combination of clinical and
economic results in one short paper, this
may be a step backwards.
Dawn Craig research fellow in health economics
dc19@york.ac.uk
John Nixon research fellow
Nigel Armstrong research fellow
Julie Glanville associate director
Jos Kleijnen director
NHS Centre for Reviews and Dissemination,
University of York, York YO10 5DD
Michael Drummond director
Centre for Health Economics, University of York
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Will the BMJ return clinical trials if
submitted without any economic results?
Editor—The implications of the BMJ’s new
policy for economic evaluations are
unclear.1
Firstly, a lag often exists between the
clinical and economic results, making simul›
taneous submission difficult. Typically, clini›
cians are eager to disseminate important
clinical results immediately. For example, the
extracorporeal membrane oxygenation
(ECMO) trial was among the first research
projects to incorporate economic evaluation
in its design from the outset. But the
preliminary clinical results were written up
and fast tracked to the Lancet before I was
even employed to continue the economic
evaluation.2 The economic evaluation was
published in the BMJ years later, having
required the clinical evidence in its analysis
and appropriate sensitivity analyses and
having undergone delay to publication.3
Would it have benefited anyone to with›
hold dramatic clinical results until the
economic results were ready? Clinical results
are often more generalisable to an inter›
national audience than the concurrent
economic results. The limitations of any
clinical information in the absence of
economic evidence should be made explicit.
The pertinent concern is surely to ensure
relevant policy makers exercise restraint
until the full information is available.
Secondly, no incentive is given in the
BMJ policy for clinicians to change their
practice. Presumably clinicians send results
to the Lancet for higher impact factors and
wider dissemination. If economists cannot
persuade colleagues to submit the clinical
paper alongside the economic paper to the
BMJ, they will resort to submitting results to
economic journals for which a different style
for different specialist audiences would be
required, ensuring even poorer dissemina›
tion to clinical audiences and policy makers.
Finally, your editorial emphasised strong
support for keeping clinical and economic
results together, and Smith told us to send
“somebody else your clinical results and us
your economic results, and we will send
them back, politely.” May I therefore ask,
politely, is the converse also true? Will you
return clinical trials if submitted without any
economic results?
Tracy Roberts lecturer in health economics
University of Birmingham, Health Economics
Facility, Birmingham B15 2RT
t.e.roberts@bham.ac.uk
1 Smith R. New BMJ policy on economic evaluations. BMJ
2002;325:1124. (16 November.)
2 UK Collaborative ECMO (Extracorporeal Membrane
Oxygenation) Trial Group. UK collaborative randomised
trial of neonatal extracorporeal membrane oxygenation.
Lancet 1996; 348:75›82
3 Roberts TE. Extracorporeal Membrane Oxygenation Eco›
nomics Working Group on behalf of the Extracorporeal
Membrane Oxygenation Trial Steering Group. Economic
evaluation and randomised trial. BMJ 1998;317:911›6.
Economic evaluations should be judged
on scientific merit
Editor—Health economists have been
grateful for the BMJ’s hitherto supportive
stance towards the publication of economic
evaluations. The proposed new policy not to
publish economic evaluations unless also
offered the clinical results is disappointing
and misjudged.1
Firstly, this policy denies the fact that,
although clinical and economic results from
a trial are both components of an overall
evaluation, they also have many differences,
often including the funding agencies sup›
porting them, the researchers, and the
timescale over which they are performed
and published. Perhaps most importantly,
important trials are often prepared for an
international audience, but economic evalu›
ations usually relate to specific healthcare
systems; large trials may generate the need
for several country specific economic evalu›
ations.
These differences justify researchers in
choosing to submit clinical and economic
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results to different journals, and entitle jour›
nals to use different criteria when deciding
whether to publish or reject. Consequently,
as in other disciplines, research findings that
are closely related and possibly interdepend›
ent often appear in different journals. That
poses no great problem to readers, espe›
cially in the era of electronic publication
championed by the BMJ.
Secondly, what is the likely effect of this
policy? Researchers aim to publish where
they judge they make most impact. Surely
no one will forgo an opportunity to publish
trial results in the Lancet simply because the
BMJ will not then consider publishing an
economic evaluation?
Smith’s editorial included no positive
proposals to make the BMJ a more attractive
outlet for trial results. Instead, this policy will
inevitably mean turning away well con›
ducted empirical research—such as the eco›
nomic analysis of the multicentre aneurysm
screening study that occasioned this
announcement2—on strictly non›scientific
grounds. Arguably these are precisely the
more scientifically important papers, leaving
the BMJ with a greater preponderance of
non›trial based economic analyses and data›
free “think pieces.” This is hardly the route to
improving the journal’s impact on the adop›
tion of new treatments or technologies.
Smith admits this new policy owes
something to petulance but nevertheless
defends it as reasonable. We think it is
unreasonable and ask him to reconsider.
Alastair M Gray professor of health economics
alastair.gray@ihs.ox.ac.uk
Andrew Briggs NHS public health career scientist
Philip Clarke research fellow
University of Oxford, Oxford OX3 7LF
We are currently involved in economic analyses
of several large trials whose clinical results have
recently been published in other journals,
including the Lancet. If adopted, this policy will
deny us the opportunity to have our scientific
research results considered for publication by
the BMJ .
1 Smith R. New BMJ policy on economic evaluations. BMJ
2002;325:1124. (16 November.)
2 Multicentre Aneurysm Screening Study Group. Multi›
centre aneurysm screening study (MASS): cost effective›
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trial. BMJ 2002;315:1135›41. (16 November.)
Economic evaluations are often based on
many studies
Editor—I understand the reasons for the
new policy on publishing economic evalua›
tion studies,1 but it is not clear how this will
apply to many of the best evaluations that
are based on reviews of many randomised
controlled trials and other clinical studies,
and use modelling to assess outcomes and
cost effectiveness. There is no reason to
exclude such studies.
If the new policy is to work it is
important also for the BMJ to ensure that its
processes of review and decision making are
joined up in terms of the different
components of studies. Too often in the past
when pairs of papers were submitted or
when a single paper reported the overall
results of a study the reviewing of the
economics has been weak. Smith’s editorial
raises the point that publishing clinical
outcomes without economic ones is really
incomplete evaluation. I look forward to
results of high quality clinical trials being
rejected for want of a proper economic
evaluation.
Charles Normand professor of health economics
London School of Hygiene and Tropical Medicine,
London WC1E 7HT
charles.normand@lshtm.ac.uk
1 Smith R. New BMJ policy on economic evaluations. BMJ
2002;325:1124. (16 November.)
Will the Lancet play ball?
Editor—The debate ensuing from the BMJ’s
new policy on publication of economic
evaluations is interesting.1 2 Smith made sev›
eral important practical points, but we
believe that some broader strategic issues
still remain.
Thankfully, major research funders in
the United Kingdom increasingly require
that economic evaluation be an integral part
of the design of a clinical trial. In many ways
the BMJ’s decision is the natural extension of
this philosophy. The risk is, however, that
unless other major journals follow suit the
policy will damage the dissemination of cost
effectiveness information.
The collaboration between clinicians
and health economists is often delicate. The
pressures that this new policy will place on
this relationship will have implications for
long term cooperation. Given the pressure
to publish rapidly in high impact journals to
secure long term funding, the interests of
clinical and economic researchers will not
always coincide.
An immediate effect of this policy for
those of us participating in multidisciplinary
research is the need to agree publication
strategies at the outset of a project. It may be
that a process similar to the Lancet’s protocol
pre›approval could facilitate these discussions
by providing confidence that high quality
clinical trials including an economic evalua›
tion will be acceptable to the major journals.
Unless all researchers accept the need for
the simultaneous publication of clinical and
economic results, cost effectiveness infor›
mation may be confined to more specialist
journals, which are rarely seen by the clinical
community. The best solution would be for
the major journals to agree that clinical trials
designed to inform policy decisions must
include a high quality economic evaluation.
We would be interested to know the Lancet’s
thoughts on this issue.
Christopher J McCabe senior lecturer in health
economics
c.mccabe@sheffield.ac.uk
Jennifer Roberts senior lecturer in health economics
University of Sheffield, Sheffield S1 4DA
It is important for our research careers to be able
to publish in high impact journals.
1 Smith R. New BMJ policy on economic evaluations. BMJ
2002;325:1124. (16 November.)
2 Electronic responses to: New BMJ policy on economic
evaluations. bmj.com 2002. bmj.com/cgi/content/full/
325/7373/1124#responses (accessed 14 Feb 2003.)
Editor’s clarifications
Editor—We thank everybody who
responded to our proposal to consider for
publication economic evaluations that
accompany clinical papers only if we are
sent both the economic and the clinical
papers. More respondents are in favour than
against, but people have raised important
questions that we must answer.
This is a further clarification of our
policy.
(1) If both the clinical and the economic
paper are submitted to us we might accept
one and not the other.
(2) We will be willing to consider for
publication economic papers that are
submitted some time after the clinical paper
if the clinical paper was also submitted to us.
It will not matter if we decided not to publish
the clinical paper. We might still be willing to
publish the economic paper.
(3) We will not reject clinical papers if
they are not accompanied by an economic
evaluation. There would be a logic to such a
policy, but we are first and foremost a clinical
journal.
(4) We will be willing to consider either
papers that combine clinical and economic
results or pairs of papers. Pairs of papers will
usually be better. Our ELPS (electronic long,
paper short) policy means that we can pub›
lish long papers on bmj.com—longer than
2000 words.1 We prepare the shorter version
for the paper edition of the BMJ. Authors
approve it before publication. If we take two
papers then we will publish them together.
(5) We will continue to consider for
publication economic papers—perhaps
modelling papers—that are not related to
particular clinical papers.
Richard Smith editor
BMJ, London WC1H 9JR
1 Müllner M, Groves T. Making research papers in the BMJ
more accessible. BMJ 2002;325:456.
Self help smoking cessation in
pregnancy
Programmes for smoking cessation can
work
Editor—Moore et al show that giving
smoking cessation booklets to pregnant
women does not help them stop smoking.1
But the intervention offered to pregnant
smokers in this study was not based on pre›
viously available evidence that adding book›
lets to face to face advice does not improve
smoking cessation rates2 and that more
intensive interventions are needed to help
pregnant smokers stop smoking.3
Nevertheless, a recent meta›analysis
indicates that individually tailored materials
produced by computers increase by 80% the
odds of stopping smoking compared with
receiving no materials.2 Because computer
tailored programmes are based on the
relevant personal characteristics of each
smoker, participants may be more interested
in reading these documents and prepared to
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apply the advice included.4 5 Consequently,
individually tailored documents are 1.36
times more effective than booklets in
helping smokers stop smoking.2 In addition,
most available computer tailored pro›
grammes include a follow up, which is an
essential element in the treatment of
addictions.
Tobacco dependence is a chronic condi›
tion with relapses and often
needs prolonged treatment. It
is a serious condition that is
unlikely to be treated with
booklets alone. But computer
tailored programmes can be a
useful adjunct to pharmaco›
therapy and to advice given
by doctors and midwives. By
using new information tech›
nology (internet, text mes›
sages on cell phones, etc),
these programmes can reach
large numbers of smokers at a
low cost. Because the preva›
lence of smoking among
pregnant women has increased sharply in
many European countries in recent years,
and few doctors and midwives are trained in
treating tobacco dependence, there is an
urgent need to assess the efficacy of computer
tailored smoking cessation programmes in
pregnant smokers.
Jean›François Etter lecturer
Institute for Social and Preventive Medicine, Faculty
of Medicine, University of Geneva, CH›1211
Geneva 4, Switzerland
Jean›Francois.Etter@imsp.unige.ch
Competing interests: J F Etter developed an
effective computer tailored smoking cessation
programme, available in four languages at no
charge.
1 Moore L, Campbell R, Whelan A, Mills N, Lupton N, Mis›
selbrook E, et al. Self help smoking cessation in pregnancy:
cluster randomised controlled trial. BMJ 2002;325:1383›6.
(14 December.)
2 Lancaster T, Stead LF. Self›help interventions for smoking
cessation Cochrane Database Syst Rev 2002;(3):CD001118.
3 Lumley J, Oliver S, Waters E. Interventions for promoting
smoking cessation during pregnancy. Cochrane Database
Syst Rev 2000;(2):CD001055.
4 Brug J, Steenhuis I, van Assema P, de Vries H. The impact
of a computer›tailored nutrition intervention. Prev Med
1996;25:236›42.
5 Dijkstra A, De Vries H, Roijackers J, van Breukelen G. Tai›
loring information to enhance quitting in smokers with
low motivation to quit: three basic efficacy questions.Health
Psychol 1998;17:513›9.
What does work in Doncaster
Editor—Moore et al reported that self help
strategies to give up smoking do not work
with pregnant women.1 This is certainly the
case.
Pregnant women require sophisticated,
tailored packages to meet their individual
needs. The care they receive needs to be
delivered by highly trained specialist mid›
wives. The midwives who deliver antenatal
and postnatal care to pregnant and postnatal
women and their families need to be trained
to raise the issue of smoking with them and
refer to specialist services as necessary.
Doncaster has a history of working with
pregnant women who want to give up
smoking and it was part of the initial pilot
study with QUIT to develop and implement
a smoking and pregnancy helpline. Building
on the success from the pilot study, Doncas›
ter launched its own service, “SmokeFree
Pregnancy.” This service encompasses all of
the elements recommended for a successful
service.
Two specially trained, highly motivated
midwives have been employed to offer
flexible support to women and their families
before, during, and after preg›
nancy. They also negotiate the
use of nicotine replacement
with general practitioners.
All midwives in Doncas›
ter are trained to raise the
issue of smoking, and in the
past year 150 pregnant
women have successfully
stopped smoking as a result
of the interventions they
have received. The success of
this type of specifically tai›
lored service in Doncaster is
reflected in the percentage of
women who give up smok›
ing, which is one of the highest in England
and is seen as an example of good practice.
Tracey A Battersby midwife specialist
tracey.battersby@doncastercentralpct.nhs.uk
Lisa Fendall midwife specialist
Doncaster SmokeFree Pregnancy, Health
Promotion Development Centre, St Catherine’s
Hospital, Doncaster DN4 8QN
Carole Pougher assistant director of public health
White Rose House, Doncaster DN4 5DJ
Competing interests: None declared.
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WHO advocates investment in
global infrastructure for
outbreaks such as smallpox
Editor—In their editorial describing the
interim smallpox guidelines for the United
Kingdom Harling et al ask how countries
lacking the public health infrastructure to
respond to outbreaks and without vaccine
supplies would be able to control an
outbreak of smallpox.1
Confronted with the threat of inten›
tional release of biological agents, the World
Health Organization advocates dual use
investment in public health infrastructure to
strengthen outbreak intelligence and verifi›
cation, support the response to an outbreak,
maintain an emergency vaccine reserve, and
provide public health information.
In 2002 the World Health Assembly
urged countries to share expertise, supplies,
and resources, and asked WHO to develop
collective mechanisms to contain or mitigate
the impact of such a global health threat.2
Since the successful eradication programme
ended in 1979 WHO has managed an emer›
gency stockpile of smallpox vaccine, which
now consists of some 500 000 doses.3 Access
to stockpiled vaccine is restricted to contain›
ing epidemiologically and virologically con›
firmed outbreaks of smallpox. The organis›
ation has built an adequate global reserve as a
critical element of smallpox preparedness by
engaging with a global health security
initiative that has undertaken to support and
increase WHO’s existing global vaccine
reserve and encourage others to do the same.
WHO has been working intensively to
provide member states with technical guid›
ance and help, improving preparedness for
epidemics of natural or intentional origin.
The organisation’s global alert and response
programme detects rumours of outbreaks,
verifies or refutes such rumours with the
affected countries, and rapidly offers technical
and operational support through the global
outbreak alert and response network.4 Since
2000, investigations by WHO have refuted 13
smallpox rumours.
Other support for preparedness is
through training in collaboration with the
US Centers for Disease Control and Preven›
tion to recognise and respond to smallpox.
Technical guidance on immunisation, diag›
nosis, and other information on smallpox
for healthcare professionals and the public
is available on the WHO website (www.
who.int/csr/disease/smallpox/en/).
WHO recognises that countries may
wish to identify key workers and immunise
them to allow a rapid response to a smallpox
outbreak. It is in keeping with WHO policy
for countries to devise and implement such
a plan in line with their own assessment of
national infrastructure and needs.
Cathy E Roth medical officer, global alert and response
rothc@who.int
Patrick Drury project manager, global alert and
response network, global alert and response
Roberta Andraghetti medical officer, global alert and
response
Ray R Arthur project leader, viral haemorrhagic fevers,
arbovirus and orthopoxvirus infections, global alert and
response
Michael J Ryan team coordinator, global alert and
response
Guenael Rodier director, department of communicable
diseases surveillance and response
Department of Communicable Diseases
Surveillance and Response, Communicable
Diseases Cluster, World Health Organization, 1211
Geneva, Switzerland
1 Harling R, Morgan D, Edmunds WJ, Campbell H. Interim
smallpox guidelines for the United Kingdom. BMJ
2002;325:1371›2. (14 December.)
2 Public health response to natural occurrence, accidental
release or deliberate use of biological and chemical agents
or radionuclear material that affect health. World Health
Assembly resolution WHA 55.16, 2002. www.who.int/gb/
EB_WHA/PDF/WHA55/ewha5516.pdf (accessed 10 Feb
2003).
3 World Health Organization. The global eradication of
smallpox: final report of the Global Commission for the
Certification of Smallpox Eradication. Geneva: WHO,
1980. http://whqlibdoc.who.int/publications/a41438.pdf
(accessed 10 Feb 2003).
4 Heymann DL, Rodier GR. Hot spots in a wired world. Lan›
cet Infect Dis 2001:1:345›53.
Polyspecific snake antivenom
may help in antivenom crisis
Editor—In Africa snakebites cause thou›
sands of deaths annually and much perma›
nent physical disability, but the supply of
antivenom, the only specific treatment, is
threatened by commercial pressures and
privatisation. This has been caused over the
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past few years by the cessation of antivenom
manufacture by Behringwerke in Germany,
greatly reduced production by Aventis
Pasteur in France, and the threat to
continued production by Africa’s sole
remaining producer, the African Health
Laboratory Service in Johannesburg.
Without antivenom, human suffering
and death from snake bite are increasing,
especially in west Africa.1 Only conservative
treatment is possible, or the use of ineffective
antivenoms manufactured in Asia or dan›
gerous traditional remedies.
In February 2001 a workshop held by
the World Health Organization identified
interregional collaboration as the only short
term solution.2 Colombia’s national institute
for public health responded by offering to
develop a prototype pan›African poly›
specific antivenom.
Venoms from nine species of Echis, Bitis,
and Naja were selected as being medically the
most important in Africa (a mamba
antivenom is being developed separately).
Horses were hyperimmunised with 13 Afri›
can venoms using the Colombian institute’s
standard protocol. The neutralising potency
of the equine antiserum in WHO standard
preclinical assays against five intravenous
median lethal doses of the individual and
pooled venoms was sufficiently high to justify
the purification of the crude antiserum to
produce a definitive antivenom.3
In preclinical tests this antivenom showed
good neutralising potency against the ven›
oms covered by the African Health Labora›
tory Service’s polyspecific antivenom. The
new antivenom also neutralised the venoms
of saw scaled vipers (genus Echis) (ED50 14.3
ìl/mouse) as effectively as both the African
Health Laboratory Service’s Echis antivenom
(12.8 ìl/mouse) and Micropharm’s Echis ocel›
latus Fab fragment antivenom (13.0
ìl/mouse.4 Unlike these two monospecific
antivenoms, the pan›African antivenom pow›
erfully neutralises the venom of Bitis arietans
(1.3 ìl/mouse) and has moderate activity
against Naja nigricollis venom (73.0
ìl/mouse). These species cause most serious
snakebites in Africa.
Another polyspecific African antivenom
(developed in Costa Rica) and a new Micro›
pharm monospecific E ocellatus F(ab′)2
fragment antivenom are undergoing pre›
clinical testing. These three antivenoms will
be compared by randomised controlled
trials in Nigeria.
G D Laing research fellow
R A Harrison research fellow
R D G Theakston professor of medical biology
r.d.g.theakston@liverpool.ac.uk
Liverpool School of Tropical Medicine, Liverpool
L3 5QA
J M Renjifo coordinator
Grupo Antivenenos, Instituto Nacional de Salud,
Bogota, Colombia
A Nasidi director, special projects
Federal Ministry of Health, Abuja, Nigeria
J M Gutierrez professor, research division
Instituto Clodomiro Picado, University of Costa
Rica, San JosØ, Costa Rica
D A Warrell professor of tropical medicine
Nuffield Department of Clinical Medicine,
University of Oxford OX3 9DU
1 Theakston RDG, Warrell DA. Crisis in snake antivenom
supply for Africa. Lancet 2000;356:2104.
2 World Health Organization. Report of a WHO workshop on
the standardization and control of antivenoms. Geneva: WHO
(in press). (Workshop held 7›9 February 2001.)
3 World Health Organization. Progress in the characterization
of venoms and standardization of antivenoms. Geneva: WHO,
1981. (WHO offset publication No 58.)
4 Meyer WP, Habib HG, Onayade AA, Yakubu A, Smith DC,
Nasidi A, et al. First clinical experience with a new ovine
Fab Echis ocellatus snake bite antivenom in Nigeria:
randomised comparative trial with Institute Pasteur serum
(Ipser) African antivenom. Am J Trop Med Hyg
1997;56:291›303.
Randomised controlled trial
for twin delivery
Editor—The article by Smith et al is a
timely retrospective cohort study, in which
the possible benefit of planned caesarean
section for twins is suggested.1 A meta›
analysis of available studies did not show any
appreciable difference in neonatal out›
comes, but pointed out that available data
are mainly level 2, being based largely on
retrospective cohort studies.2
On the basis of these data and data from
the Atlee Nova Scotia perinatal database we
have estimated that planned vaginal delivery
of twins at 32 weeks or older carries a risk of
perinatal mortality or serious morbidity of
about 4%. To show a reduction in this to 2%
requires 2500 patients (power 80%, alpha
error 0.05, two sided). On the basis of our
experience with the term breech trial we
believe that such a trial is possible, and with
support from over 175 centres we have sub›
mitted such a proposal to the Canadian
Institutes for Health Research. We caution
against any radical change in practice
without strong evidence from a well
designed randomised controlled trial. Any
centre that is interested should contact our
group at jon.barrett@swchsc.on.ca
Jon F R Barrett associate professor
University of Toronto, SWCHSC and Maternal
Infant Research Unit, 76 Grenville Street, Toronto,
Canada M5S 1B6
jon.barrett@swchsc.on.ca
for The Twin Birth Study Collaborative Group
1 Smith CS, Pell JA, Dobbie R. Birth order, gestational age,
and risk of delivery related perinatal death in twins: retro›
spective cohort study. BMJ 2002;325:1004›8. (2 Novem›
ber.)
2 Hogle K, Hutton E, McBrien KA, Barrett J, Hannah ME.
Caesarean delivery for twins: a systematic review and meta
analysis. Am J Obstet Gynecol (in press.)
Thrombolysis with recombinant
streptokinase in Cuba
Editor—Analysis of the causes of the low
rate (21%) of thrombolysis for acute
myocardial infarction in England and Wales
described by Mayor would be interesting.1 In
Cuba thrombolysis with home manufac›
tured recombinant streptokinase has been
widespread since 1993. When this proce›
dure was introduced nationwide, the overall
proportion of patients receiving treatment
was a little above 30%.
The main reason why thrombolysis was
not given was largely because patients
arrived at hospital more than 12 hours after
the onset of symptoms. Other causes were
non›ST elevation and contraindications for
thrombolysis, such as possible causes of
bleeding.2 The management system for
patients has, however, become more effi›
cient, with patients arriving earlier. Also doc›
tors in emergency departments are more
acquainted with the product, so currently
the rate of thrombolysis is around 50%
nationwide and even 70% in some units.
The report also says that streptokinase
should not be given twice because of the for›
mation of anti›streptokinase antibodies. We
found that almost all patients had low titres
of anti›streptokinase antibodies before
thrombolysis; they increased rapidly after
treatment but then started to fall.3 After six
months the average anti›streptokinase titre
was roughly still enough to neutralise the
thrombolytic activity in plasma achieved
with the 1.5 million unit dose. After one year
the titres had almost returned to pre›
treatment values. Given these data, we think
that streptokinase can be given again after a
case by case analysis of risks and benefits six
months after the first administration and
surely after one year.
Pedro A Lopez›Saura head of clinical trials
Centre for Biological Research, PO Box 6162,
CP 10600, Havana, Cuba
lopez.saura@cigb.edu.cu
1 Mayor S. NICE recommends greater use of thrombolytics
in acute myocardial infarction. BMJ 2002;325:1057. (9
November.)
2 TERIMA Group. TERIMA›2: National extension of
thrombolytic treatment with recombinant streptokinase in
acute myocardial infarct in Cuba. Thromb Haemost
2000;84:949›54.
3 Mainet D, del Rosario M, Toruncha A, Prats P, Valenzuela
C, López›Saura P. Similar, more than 6›month persisted,
antibody and neutralizing activity responses in patients
with acute myocardial infarction treated with recombinant
or natural streptokinase. Fibrinolysis Proteolysis 1998;
12:301›9.
Checklists for myocardial
infarction should be precise
Editor—Savage and Channer highlight a
serious problem in their editorial on
managing acute myocardial infarction.1
Doctors are under increasing pressure to
reduce door to needle times to below 30
(possibly 20) minutes and often now
delegate this task to thrombolysis nurses.
Such nurses are accountable for the door to
needle time and are often blamed if the tar›
gets of national service frameworks are not
met. Often delay occurs in calling a
thrombolysis nurse, such that the nurse has
very little thinking time if he or she is to stay
within the target.
Everyone involved should know that sta›
tistics on door to needle times should apply
only to those patients in whom the diagnosis
is definite and no possible contraindication
exists. If potential problems are identified
with either the diagnosis or a potential
contraindication the clock should stop
ticking. The thrombolysis nurse should then
have ready access to someone with the
experience and knowledge to weigh the
risks and benefits in an individual patient.
Although any decision should be made as
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quickly as possible, sufficient time should be
allowed to avoid hasty or ill considered deci›
sions. Delays in calling the thrombolysis
nurse or junior doctor should be minimised.
Every hospital in the United Kingdom
has a different checklist for assessing
patients. Is it not time for a nationally agreed
list of relative and absolute contraindications
to thrombolysis? Such a list should be
precise and specific in its statements, not
simply say uncontrolled hypertension. In
addition, in some groups of patients the
benefits of thrombolysis are higher and the
complications are worth risking. Other
groups of patients may have less potential
benefit and therefore need a more cautious
strategy. Thus users of the checklist require
easy access to expert opinion.
G Alastair Cooke consultant cardiologist
King’s Mill Hospital, Sutton in Ashfield,
Nottinghamshire NG17 4JL
alastaircooke@doctors.org.uk
1 Savage MW, Channer KS. Improving the management of
acute myocardial infarction. BMJ 2002;325:1185›6. (23
November.)
Copying letters to patients
Psychiatrists omit information from
letters when they know patients will be
sent copies
Editor—From April 2004 patients will
receive copies of all correspondence
between clinicians working in the NHS as a
matter of course.1 2 Previous research sup›
ports the view reported in Eaton’s news item
that patients appreciate this practice3–5; how›
ever, the way its national introduction will
affect doctors’ work is much less clear. We
audited how psychiatrists’ practice is affected
when letters are to be copied to patients.
All 76 new patients who attended two
general psychiatry outpatient clinics (one
rural, one inner city) from January 2002 to
July 2002 were included in the pilot study, as
were all eight psychiatrists who worked in
these clinics during this time. After the
assessment patients were sent a copy of the
psychiatrist’s letter to the general prac›
titioner and asked to complete a short ques›
tionnaire on their evaluation of the letter.
Psychiatrists were asked whether anything of
importance had been omitted from the
letter that they would usually have included,
and if so, the reason and how the omitted
information would be communicated to
general practitioners.
Fifty six of the 76 letters (74%) were sent
to the patient in an unaltered form (table). In
three cases the psychiatrists thought it inap›
propriate for the patient to receive a copy of
the letter, citing concerns over patients’
distress. In 17 cases clinicians made omis›
sions, mainly of parts of the history. Sixteen
of these 17 patients were treated by just two
of the eight doctors.
Reasons cited for omission were fear of
distressing the patient (14 instances), con›
cern about people other than the patient
having access to information (four
instances), and protection of information
supplied by third parties (two instances).
General practitioners were informed of the
omitted information, either by letter or in
person.
Forty patients (55%) responded to the
questionnaires. Most patients (33 out of 40)
wished to continue receiving copies of
correspondence.
Sending patients a copy of the letter to
the general practitioner after a psychiatric
consultation is valued and appreciated by
patients; some doctors are, however, worried
about distressing patients by what they write
and consequently tend to omit information.
Some training and reassurance about this
practice may be needed before implementa›
tion.
Graham K Murray research associate
Department of Psychiatry, University of Cambridge,
Box 189, Addenbrooke’s Hospital, Cambridge CB2
2QQ
gm285@cam.ac.uk
Harpal Nandhra specialist registrar, psychiatry
Fair Mile Hospital, Wallingford, Oxon OX10 9HH
Nigel Hymas consultant psychiatrist
Box 179, Addenbrooke’s Hospital
Neil Hunt consultant psychiatrist
Fulbourn Hospital, Cambridge CB1 5EF
1 Department of Health. The NHS plan. London: Stationery
Office, 2000.
2 Working Group on Copying Letters to Patients. Copying
letters to patients: a report to the Department of Health and draft
good practice guidelines for consultation. Leeds: Department
of Health, 2002.
3 Eaton L. Patients should be sent copies of doctors’ letters
about them. BMJ 2002;325:1056. (9 December.)
4 Asch R, Price J, Hawks G. Psychiatric out›patients’
reactions to summary letters of their consultations. Br J
Med Psychol 1991;64:3›9.
5 Thomas P. Writing letters to patients. Psychiatr Bull
1998;22:542›5.
Copying letters can help avoid
communications nightmare
Editor—As the parents of a young person
with myalgic encephalomyelitis/chronic
fatigue syndrome who has regular appoint›
ments at paediatric outpatient clinics, we
have received copies of all follow up letters
to our son’s general practitioner for over
three years now.1
These have been provided as a matter
of course, but we would have otherwise
requested them. Copies of follow up
letters are also copied to my son’s
educational welfare officer, school heads,
and special educational needs coordinator,
as appropriate.
We have also received copies of referral
letters from his paediatric doctor to consult›
ants and heads of other hospital depart›
ments, the local education authority in
support of continuing provision of home
tuition, and examination boards in support
of “special arrangements” for GCSE exami›
nations.
Occasionally, errors in letters have
occurred, but we are in a position to pick up
on these and have them corrected. Adminis›
trative errors have also occurred—I am told,
through the use of temporary secretarial staff.
This has resulted in follow up letters being
sent to the wrong general practitioner at the
wrong surgery and to an unnamed special
educational needs coordinator at the wrong
school, evidenced by the list of copied recipi›
ents at the foot of our copies of these letters.
For parents of young people who are
unable to access mainstream education
because of long term illnesses such as myal›
gic encephalomyelitis/chronic fatigue syn›
drome the difficulties in maintaining effec›
tive liaison between school, special
educational needs coordinator, educational
welfare officer, home tuition coordinator,
general practitioner, hospital consultant,
community paediatrician, and local educa›
tion authority can be serious. In addition,
some families also deal with social services
and child and adolescent mental health
services, as well as having input from the
connections service.
For many it can be a communications
nightmare on top of an already challenging
situation. Anything that helps to improve
liaison, such as receiving copies of hospital
letters, is to be welcomed, and I would advise
all parents to ask for copies of these letters if
they do not already receive them.
Suzy Chapman carer of young person with myalgic
encephalomyelitis
Lytchett Matravers, Poole, Dorset BH16 6BG
suzychapman@greywood.freeserve.co.uk
1 Jelley D, van Zwanenberg T, Walker C, Meredith BL, Towler
HMA. Copying letters to patients. BMJ 2002;325:1359. (7
December.)
Employing users who turn
back into patients is difficult
Editor—Simpson and House conducted a
systematic review of involving users in the
delivery and evaluation of mental health
services.1
I have certainly found employing users
to be a positive experience. However, one
difficulty not mentioned in the paper is that
of subsequently treating these people as
patients again when they relapse.
The move from patient to colleague is
comparatively easy compared with the tran›
sition back to that of patient, particularly if
the Mental Health Act is needed.
Anna Knight consultant psychiatrist
Yeovil, Somerset BA20 2BX
anna.knight@sompar.nhs.uk
1 Simpson EL, House AO. Involving users in the delivery
and evaluation of mental health services: systematic review.
BMJ 2002;325:1265›9. (30 November.)
Results of audit of psychiatrists’ practice when
copying letters to patients
No of cases
Letter sent to patient
Copy of general practitioner’s letter 73
None 3
General practitioner’s letter with at least one
omission
17
Parts omitted
History or examination details 14
Diagnosis 3
Prognosis 6
Reason for omission
Fear of distressing patient 14
Other concerns 6
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